| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697396 | Bulletin du Cancer | 2017 | 10 Pages |
Abstract
Neoadjuvant systemic therapies have been extensively evaluated in luminal breast cancer. Conventional cytotoxic chemotherapy increases breast conservation rate, albeit with a low level of complete pathological response of uncertain clinical significance. Endocrine therapies allow similar clinical results with much less side effects. Biological criteria of response to endocrine therapies are still being defined. The neoadjuvant setting must be used for early development of new compounds and to further document biological mechanisms of sensitivity and resistance to treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paul H. Cottu,